Search

Your search keyword '"Pierre, Germaine"' showing total 119 results
Start Over Author "Pierre, Germaine"
119 results on '"Pierre, Germaine"'

1. Liver transplantation in ornithine transcarbamylase deficiency: A retrospective multicentre cohort study

Author

Seker Yilmaz, Berna, Baruteau, Julien, Chakrapani, Anupam, Champion, Michael, Chronopoulou, Efstathia, Claridge, Lee C., Daly, Anne, Davies, Catherine, Davison, James, Dhawan, Anil, Grunewald, Stephanie, Gupte, Girish L., Heaton, Nigel, Lemonde, Hugh, McKiernan, Pat, Mills, Philippa, Morris, Andrew A.M., Mundy, Helen, Pierre, Germaine, Rajwal, Sanjay, Sivananthan, Siyamini, Sreekantam, Srividya, Stepien, Karolina M., Vara, Roshni, Yeo, Mildrid, and Gissen, Paul

Published
2023
Full Text
View/download PDF

3. Retrospective Review of Positive Newborn Screening Results for Isovaleric Acidemia and Development of a Strategy to Improve the Efficacy of Newborn Screening in the UK

Author

Carling, Rachel S., primary, Hedgethorne, Katy, additional, Chakrapani, Anupam, additional, Hall, Patricia L., additional, Flynn, Nick, additional, Greenfield, Toby, additional, Moat, Stuart J., additional, Ssali, Joshua, additional, Shakespeare, Lynette, additional, Taj, Nazia, additional, Wu, Teresa H. Y., additional, Anderson, Mark, additional, Ghosh, Arunabha, additional, Lemonde, Hugh, additional, Pierre, Germaine, additional, Sharrard, Mark, additional, Sreekantam, Sreevidya, additional, and Bonham, James R., additional

Published
2024
Full Text
View/download PDF

4. Syndromic disorders caused by gain-of-function variants in KCNH1, KCNK4, and KCNN3—a subgroup of K+ channelopathies

Author

Gripp, Karen W., Smithson, Sarah F., Scurr, Ingrid J., Baptista, Julia, Majumdar, Anirban, Pierre, Germaine, Williams, Maggie, Henderson, Lindsay B., Wentzensen, Ingrid M., McLaughlin, Heather, Leeuwen, Lisette, Simon, Marleen E. H., van Binsbergen, Ellen, Dinulos, Mary Beth P., Kaplan, Julie D., McRae, Anne, Superti-Furga, Andrea, Good, Jean-Marc, and Kutsche, Kerstin

Published
2021
Full Text
View/download PDF

5. Retrospective Review of Positive Newborn Screening Results for Isovaleric Acidemia and Development of a Strategy to Improve the Efficacy of Newborn Screening in the UK.

Author

Carling, Rachel S, primary, Hedgethorne, Katy, additional, Chakrapani, Anupam, additional, Hall, Patricia L, additional, Flynn, Nick, additional, Greenfield, Toby, additional, Moat, Stuart J., additional, Ssali, Joshua, additional, Shakespeare, Lynette, additional, Taj, Nazia, additional, Anderson, Mark, additional, Wu, Teresa H.Y., additional, Ghosh, Arunabha, additional, Lemonde, Hugh, additional, Pierre, Germaine, additional, Sharrard, Mark, additional, Sreekantam, Sreevidya, additional, and Bonham, James R, additional

Published
2024
Full Text
View/download PDF

6. Mutant PTPMT1 disrupts cardiolipin metabolism and mitochondrial bioenergetics leading to a neurodevelopmental syndrome

Author

Falabella, Micol, Pizzamiglio, Chiara, Tabara, Luis Carlos, Munro, Benjamin, Abdel-Hamid, Mohamed S., Sonmezler, Ece, Macken, William L., Lu, Shanti, Tilokani, Lisa, Flannery, Padraig J., Pope, Simon A.S., Heales, Simon J.R., Hammadi, Dania B.H., Alston, Charlotte L., Taylor, Robert W., Lochmuller, Hanns, Chronopoulou, Efstathia, Pierre, Germaine, Maroofian, Reza, Hanna, Michael G., Taanman, Jan-Willem, Hiz, Semra, Oktay, Yavuz, Zaki, Maha S., Horvath, Rita, Prudent, Julien, and Pitceathly, Robert D.S.

Published
2024
Full Text
View/download PDF

8. MT-ND5 Mutation Exhibits Highly Variable Neurological Manifestations at Low Mutant Load

Author

Ng, Yi Shiau, Lax, Nichola Z., Maddison, Paul, Alston, Charlotte L., Blakely, Emma L., Hepplewhite, Philippa D., Riordan, Gillian, Meldau, Surita, Chinnery, Patrick F., Pierre, Germaine, Chronopoulou, Efstathia, Du, Ailian, Hughes, Imelda, Morris, Andrew A., Kamakari, Smaragda, Chrousos, Georgia, Rodenburg, Richard J., Saris, Christiaan G.J., Feeney, Catherine, Hardy, Steven A., Sakakibara, Takafumi, Sudo, Akira, Okazaki, Yasushi, Murayama, Kei, Mundy, Helen, Hanna, Michael G., Ohtake, Akira, Schaefer, Andrew M., Champion, Mike P., Turnbull, Doug M., Taylor, Robert W., Pitceathly, Robert D.S., McFarland, Robert, and Gorman, Gráinne S.

Published
2018
Full Text
View/download PDF

11. Clinical, biochemical and genetic spectrum of 70 patients with ACAD9 deficiency: is riboflavin supplementation effective?

Author

Repp, Birgit M., Mastantuono, Elisa, Alston, Charlotte L., Schiff, Manuel, Haack, Tobias B., Rötig, Agnes, Ardissone, Anna, Lombès, Anne, Catarino, Claudia B., Diodato, Daria, Schottmann, Gudrun, Poulton, Joanna, Burlina, Alberto, Jonckheere, An, Munnich, Arnold, Rolinski, Boris, Ghezzi, Daniele, Rokicki, Dariusz, Wellesley, Diana, Martinelli, Diego, Wenhong, Ding, Lamantea, Eleonora, Ostergaard, Elsebet, Pronicka, Ewa, Pierre, Germaine, Smeets, Hubert J. M., Wittig, Ilka, Scurr, Ingrid, de Coo, Irenaeus F. M., Moroni, Isabella, Smet, Joél, Mayr, Johannes A., Dai, Lifang, de Meirleir, Linda, Schuelke, Markus, Zeviani, Massimo, Morscher, Raphael J., McFarland, Robert, Seneca, Sara, Klopstock, Thomas, Meitinger, Thomas, Wieland, Thomas, Strom, Tim M., Herberg, Ulrike, Ahting, Uwe, Sperl, Wolfgang, Nassogne, Marie-Cecile, Ling, Han, Fang, Fang, Freisinger, Peter, Van Coster, Rudy, Strecker, Valentina, Taylor, Robert W., Häberle, Johannes, Vockley, Jerry, Prokisch, Holger, and Wortmann, Saskia

Published
2018
Full Text
View/download PDF

13. Severe Congenital Myopathy and Neuropathy with Congenital Cataracts due to GFER Variant: A Neuropathological Study

Author

Sanchez-Marco, Silvia Beatriz, additional, Pierre, Germaine, additional, Sharples, Peta, additional, Love, Seth, additional, Urankar, Kathryn, additional, Hilliard, Tom, additional, Lunt, Peter, additional, Churchill, Amanda, additional, Aungraheeta, Riyaad, additional, Dallosso, Anthony, additional, Evans, Julie, additional, Williams, Maggie, additional, and Majumdar, Anirban, additional

Published
2022
Full Text
View/download PDF

16. Syndromic disorders caused by gain-of-function variants in KCNH1, KCNK4, and KCNN3-a subgroup of K+ channelopathies

Author

Genetica Klinische Genetica, Genetica Sectie Genoomdiagnostiek, Child Health, Gripp, Karen W, Smithson, Sarah F, Scurr, Ingrid J, Baptista, Julia, Majumdar, Anirban, Pierre, Germaine, Williams, Maggie, Henderson, Lindsay B, Wentzensen, Ingrid M, McLaughlin, Heather, Leeuwen, Lisette, Simon, Marleen E H, van Binsbergen, Ellen, Dinulos, Mary Beth P, Kaplan, Julie D, McRae, Anne, Superti-Furga, Andrea, Good, Jean-Marc, Kutsche, Kerstin, Genetica Klinische Genetica, Genetica Sectie Genoomdiagnostiek, Child Health, Gripp, Karen W, Smithson, Sarah F, Scurr, Ingrid J, Baptista, Julia, Majumdar, Anirban, Pierre, Germaine, Williams, Maggie, Henderson, Lindsay B, Wentzensen, Ingrid M, McLaughlin, Heather, Leeuwen, Lisette, Simon, Marleen E H, van Binsbergen, Ellen, Dinulos, Mary Beth P, Kaplan, Julie D, McRae, Anne, Superti-Furga, Andrea, Good, Jean-Marc, and Kutsche, Kerstin

Published
2021

18. Bi-allelic Mutations in Phe-tRNA Synthetase Associated with a Multi-system Pulmonary Disease Support Non-translational Function

Author

Xu, Zhiwen, Lo, Wing-Sze, Beck, David B., Schuch, Luise A., Oláhová, Monika, Kopajtich, Robert, Chong, Yeeting E., Alston, Charlotte L., Seidl, Elias, Zhai, Liting, Lau, Ching-Fun, Timchak, Donna, LeDuc, Charles A., Borczuk, Alain C., Teich, Andrew F., Juusola, Jane, Sofeso, Christina, Müller, Christoph, Pierre, Germaine, Hilliard, Tom, Turnpenny, Peter D., Wagner, Matias, Kappler, Matthias, Brasch, Frank, Bouffard, John Paul, Nangle, Leslie A., Yang, Xiang-Lei, Zhang, Mingjie, Taylor, Robert W., Prokisch, Holger, Griese, Matthias, Chung, Wendy K., and Schimmel, Paul

Subjects
cholesterol pneumonitis, interstitial lung disease, Lung Diseases, Male, Heterozygote, tRNA synthetase, Adolescent, missense mutation, multi-system disease, non-coding variant, Infant, Genes, Recessive, bi-allelic mutation, Article, Amino Acyl-tRNA Synthetases, cerebral calcifications, Charcot-Marie-Tooth Disease, Child, Preschool, Protein Biosynthesis, Mutation, Humans, Female, non-canonical function, exome sequencing, Alleles
Abstract

The tRNA synthetases catalyze the first step of protein synthesis and have increasingly been studied for their nuclear and extra-cellular ex-translational activities. Human genetic conditions such as Charcot-Marie-Tooth have been attributed to dominant gain-of-function mutations in some tRNA synthetases. Unlike dominantly inherited gain-of-function mutations, recessive loss-of-function mutations can potentially elucidate ex-translational activities. We present here five individuals from four families with a multi-system disease associated with bi-allelic mutations in FARSB that encodes the beta chain of the alpha2beta2 phenylalanine-tRNA synthetase (FARS). Collectively, the mutant alleles encompass a 5′-splice junction non-coding variant (SJV) and six missense variants, one of which is shared by unrelated individuals. The clinical condition is characterized by interstitial lung disease, cerebral aneurysms and brain calcifications, and cirrhosis. For the SJV, we confirmed exon skipping leading to a frameshift associated with noncatalytic activity. While the bi-allelic combination of the SJV with a p.Arg305Gln missense mutation in two individuals led to severe disease, cells from neither the asymptomatic heterozygous carriers nor the compound heterozygous affected individual had any defect in protein synthesis. These results support a disease mechanism independent of tRNA synthetase activities in protein translation and suggest that this FARS activity is essential for normal function in multiple organs.

Published
2018

20. Dietary Management, Clinical Status and Outcome of Patients with Citrin Deficiency in the UK

Author

Pinto, Alex, primary, Ashmore, Catherine, additional, Batzios, Spyros, additional, Daly, Anne, additional, Dawson, Charlotte, additional, Dixon, Marjorie, additional, Evans, Sharon, additional, Green, Diane, additional, Gribben, Joanna, additional, Hunjan, Inderdip, additional, Jameson, Elisabeth, additional, Newby, Camille, additional, Pierre, Germaine, additional, Rajwal, Sanjay, additional, Robertson, Louise, additional, Santra, Si, additional, Sharrard, Mark, additional, Vara, Roshni, additional, White, Lucy, additional, Wilcox, Gisela, additional, Yilmaz, Ozlem, additional, and MacDonald, Anita, additional

Published
2020
Full Text
View/download PDF

21. Early‐onset coenzyme Q10 deficiency associated with ataxia and respiratory chain dysfunction due to novel pathogenic COQ8A variants, including a large intragenic deletion

Author

Cotta, Ana, primary, Alston, Charlotte L., additional, Baptista‐Junior, Sidney, additional, Paim, Julia F., additional, Carvalho, Elmano, additional, Navarro, Monica M., additional, Appleton, Marie, additional, Ng, Yi Shiau, additional, Valicek, Jaquelin, additional, da‐Cunha‐Junior, Antonio L., additional, Lima, Maria I., additional, Rocque Ferreira, Alessandra, additional, Takata, Reinaldo I., additional, Hargreaves, Iain P., additional, Gorman, Gráinne S., additional, McFarland, Robert, additional, Pierre, Germaine, additional, and Taylor, Robert W., additional

Published
2020
Full Text
View/download PDF

23. Clinical presentation and natural history of Barth Syndrome: An overview.

Author

Taylor, Carolyn, Rao, Emily S., Pierre, Germaine, Chronopoulou, Estathia, Hornby, Brittany, Heyman, Andrea, and Vernon, Hilary J.

Abstract

Barth Syndrome is a rare X‐linked disorder caused by pathogenic variants in the gene TAFAZZIN, which encodes for an enzyme involved in the remodeling of cardiolipin, a phospholipid primarily localized to the inner mitochondrial membrane. Barth Syndrome is characterized by cardiomyopathy, skeletal myopathy, neutropenia, and growth abnormalities, among other features. In this review, we will discuss the clinical presentation and natural history of Barth Syndrome, review key features of this disease, and introduce less common clinical associations. Recognition and understanding of the natural history of Barth Syndrome are important for ongoing patient management and developing endpoints for the demonstration of efficacy of new and emerging therapies. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

26. Clinical presentation and proteomic signature of patients with TANGO2 mutations

Author

Generalitat de Catalunya, Association Française contre les Myopathies, European Research Council, European Commission, Fundació La Marató de TV3, Instituto de Salud Carlos III, Medical Research Council (UK), National Institute for Health Research (UK), Wellcome Trust, Mingirulli, Nadja, Pyle, Angela, Hathazi, Denisa, Alston, Charlotte L., Kohlschmidt, Nicolai, O'Grady, Gina, Waddell, Leigh, Evesson, Frances, Cooper, Sandra B. T., Turner, Christian, Duff, Jennifer, Topf, Ana, Yubero, Delia, Jou, Cristina, Nascimento, Andrés, Ortez, Carlos, García‐Cazorla, Angels, Gross, Claudia, O'Callaghan, María, Santra, Saikat, Preece, Maryanne A., Champion, Michael, Korenev, Sergei, Chronopoulou, Efsthatia, Anirban, Majumdar, Pierre, Germaine, McArthur, Daniel, Kyle, Thompson, Navas, Plácido, Ribes, Antonia, Tort, Frederic, Schlüter, Agatha, Pujol, Aurora, Montero, Raquel, Sarquella, Georgia, Lochmüller, Hanns, Jiménez‐Mallebrera, Cecilia, Taylor, Robert W., Artuch, Rafael, Kirschner, Janbernd, Grünert, Sarah C., Roos, Andreas, Horvath, Rita, Generalitat de Catalunya, Association Française contre les Myopathies, European Research Council, European Commission, Fundació La Marató de TV3, Instituto de Salud Carlos III, Medical Research Council (UK), National Institute for Health Research (UK), Wellcome Trust, Mingirulli, Nadja, Pyle, Angela, Hathazi, Denisa, Alston, Charlotte L., Kohlschmidt, Nicolai, O'Grady, Gina, Waddell, Leigh, Evesson, Frances, Cooper, Sandra B. T., Turner, Christian, Duff, Jennifer, Topf, Ana, Yubero, Delia, Jou, Cristina, Nascimento, Andrés, Ortez, Carlos, García‐Cazorla, Angels, Gross, Claudia, O'Callaghan, María, Santra, Saikat, Preece, Maryanne A., Champion, Michael, Korenev, Sergei, Chronopoulou, Efsthatia, Anirban, Majumdar, Pierre, Germaine, McArthur, Daniel, Kyle, Thompson, Navas, Plácido, Ribes, Antonia, Tort, Frederic, Schlüter, Agatha, Pujol, Aurora, Montero, Raquel, Sarquella, Georgia, Lochmüller, Hanns, Jiménez‐Mallebrera, Cecilia, Taylor, Robert W., Artuch, Rafael, Kirschner, Janbernd, Grünert, Sarah C., Roos, Andreas, and Horvath, Rita

Abstract

Transport And Golgi Organization protein 2 (TANGO2) deficiency has recently been identified as a rare metabolic disorder with a distinct clinical and biochemical phenotype of recurrent metabolic crises, hypoglycemia, lactic acidosis, rhabdomyolysis, arrhythmias, and encephalopathy with cognitive decline. We report nine subjects from seven independent families, and we studied muscle histology, respiratory chain enzyme activities in skeletal muscle and proteomic signature of fibroblasts. All nine subjects carried autosomal recessive TANGO2 mutations. Two carried the reported deletion of exons 3 to 9, one homozygous, one heterozygous with a 22q11.21 microdeletion inherited in trans. The other subjects carried three novel homozygous (c.262C>T/p.Arg88*; c.220A>C/p.Thr74Pro; c.380+1G>A), and two further novel heterozygous (c.6_9del/p.Phe6del); c.11‐13delTCT/p.Phe5del mutations. Immunoblot analysis detected a significant decrease of TANGO2 protein. Muscle histology showed mild variation of fiber diameter, no ragged‐red/cytochrome c oxidase‐negative fibers and a defect of multiple respiratory chain enzymes and coenzyme Q10 (CoQ10) in two cases, suggesting a possible secondary defect of oxidative phosphorylation. Proteomic analysis in fibroblasts revealed significant changes in components of the mitochondrial fatty acid oxidation, plasma membrane, endoplasmic reticulum‐Golgi network and secretory pathways. Clinical presentation of TANGO2 mutations is homogeneous and clinically recognizable. The hemizygous mutations in two patients suggest that some mutations leading to allele loss are difficult to detect. A combined defect of the respiratory chain enzymes and CoQ10 with altered levels of several membrane proteins provides molecular insights into the underlying pathophysiology and may guide rational new therapeutic interventions.

Published
2019

27. Clinical presentation and proteomic signature of patients with TANGO2 mutations

Author

Mingirulli, Nadja, primary, Pyle, Angela, additional, Hathazi, Denisa, additional, Alston, Charlotte L., additional, Kohlschmidt, Nicolai, additional, O'Grady, Gina, additional, Waddell, Leigh, additional, Evesson, Frances, additional, Cooper, Sandra B. T., additional, Turner, Christian, additional, Duff, Jennifer, additional, Topf, Ana, additional, Yubero, Delia, additional, Jou, Cristina, additional, Nascimento, Andrés, additional, Ortez, Carlos, additional, García‐Cazorla, Angels, additional, Gross, Claudia, additional, O'Callaghan, Maria, additional, Santra, Saikat, additional, Preece, Maryanne A., additional, Champion, Michael, additional, Korenev, Sergei, additional, Chronopoulou, Efsthatia, additional, Anirban, Majumdar, additional, Pierre, Germaine, additional, McArthur, Daniel, additional, Thompson, Kyle, additional, Navas, Placido, additional, Ribes, Antonia, additional, Tort, Frederic, additional, Schlüter, Agatha, additional, Pujol, Aurora, additional, Montero, Raquel, additional, Sarquella, Georgia, additional, Lochmüller, Hanns, additional, Jiménez‐Mallebrera, Cecilia, additional, Taylor, Robert W., additional, Artuch, Rafael, additional, Kirschner, Janbernd, additional, Grünert, Sarah C., additional, Roos, Andreas, additional, and Horvath, Rita, additional

Published
2019
Full Text
View/download PDF

28. Clinical, biochemical and genetic spectrum of 70 patients with ACAD9 deficiency: is riboflavin supplementation effective?

Author

UCL - SSS/IONS - Institute of NeuroScience, UCL - SSS/IONS/NEUR - Clinical Neuroscience, UCL - (SLuc) Service de neurologie pédiatrique, Repp, Birgit M., Mastantuono, Elisa, Alston, Charlotte L., Schiff, Manuel, Haack, Tobias B., Rötig, Agnes, Ardissone, Anna, Lombès, Anne, Catarino, Claudia B., Diodato, Daria, Schottmann, Gudrun, Poulton, Joanna, Burlina, Alberto, Jonckheere, An, Munnich, Arnold, Rolinski, Boris, Ghezzi, Daniele, Rokicki, Dariusz, Wellesley, Diana, Martinelli, Diego, Wenhong, Ding, Lamantea, Eleonora, Ostergaard, Elsebet, Pronicka, Ewa, Pierre, Germaine, Smeets, Hubert J. M., Wittig, Ilka, Scurr, Ingrid, de Coo, Irenaeus F. M., Moroni, Isabella, Smet, Joél, Mayr, Johannes A., Dai, Lifang, de Meirleir, Linda, Schuelke, Markus, Zeviani, Massimo, Morscher, Raphael J., McFarland, Robert, Seneca, Sara, Klopstock, Thomas, Meitinger, Thomas, Wieland, Thomas, Strom, Tim M., Herberg, Ulrike, Ahting, Uwe, Sperl, Wolfgang, Nassogne, Marie-Cécile, Ling, Han, Fang, Fang, Freisinger, Peter, Van Coster, Rudy, Strecker, Valentina, Taylor, Robert W., Häberle, Johannes, Vockley, Jerry, Prokisch, Holger, Wortmann, Saskia, UCL - SSS/IONS - Institute of NeuroScience, UCL - SSS/IONS/NEUR - Clinical Neuroscience, UCL - (SLuc) Service de neurologie pédiatrique, Repp, Birgit M., Mastantuono, Elisa, Alston, Charlotte L., Schiff, Manuel, Haack, Tobias B., Rötig, Agnes, Ardissone, Anna, Lombès, Anne, Catarino, Claudia B., Diodato, Daria, Schottmann, Gudrun, Poulton, Joanna, Burlina, Alberto, Jonckheere, An, Munnich, Arnold, Rolinski, Boris, Ghezzi, Daniele, Rokicki, Dariusz, Wellesley, Diana, Martinelli, Diego, Wenhong, Ding, Lamantea, Eleonora, Ostergaard, Elsebet, Pronicka, Ewa, Pierre, Germaine, Smeets, Hubert J. M., Wittig, Ilka, Scurr, Ingrid, de Coo, Irenaeus F. M., Moroni, Isabella, Smet, Joél, Mayr, Johannes A., Dai, Lifang, de Meirleir, Linda, Schuelke, Markus, Zeviani, Massimo, Morscher, Raphael J., McFarland, Robert, Seneca, Sara, Klopstock, Thomas, Meitinger, Thomas, Wieland, Thomas, Strom, Tim M., Herberg, Ulrike, Ahting, Uwe, Sperl, Wolfgang, Nassogne, Marie-Cécile, Ling, Han, Fang, Fang, Freisinger, Peter, Van Coster, Rudy, Strecker, Valentina, Taylor, Robert W., Häberle, Johannes, Vockley, Jerry, Prokisch, Holger, and Wortmann, Saskia

Abstract

BACKGROUND: Mitochondrial acyl-CoA dehydrogenase family member 9 (ACAD9) is essential for the assembly of mitochondrial respiratory chain complex I. Disease causing biallelic variants in ACAD9 have been reported in individuals presenting with lactic acidosis and cardiomyopathy. RESULTS: We describe the genetic, clinical and biochemical findings in a cohort of 70 patients, of whom 29 previously unpublished. We found 34 known and 18 previously unreported variants in ACAD9. No patients harbored biallelic loss of function mutations, indicating that this combination is unlikely to be compatible with life. Causal pathogenic variants were distributed throughout the entire gene, and there was no obvious genotype-phenotype correlation. Most of the patients presented in the first year of life. For this subgroup the survival was poor (50% not surviving the first 2 years) comparing to patients with a later presentation (more than 90% surviving 10 years). The most common clinical findings were cardiomyopathy (85%), muscular weakness (75%) and exercise intolerance (72%). Interestingly, severe intellectual deficits were only reported in one patient and severe developmental delays in four patients. More than 70% of the patients were able to perform the same activities of daily living when compared to peers. CONCLUSIONS: Our data show that riboflavin treatment improves complex I activity in the majority of patient-derived fibroblasts tested. This effect was also reported for most of the treated patients and is mirrored in the survival data. In the patient group with disease-onset below 1 year of age, we observed a statistically-significant better survival for patients treated with riboflavin.

Published
2018

29. Clinical, biochemical and genetic spectrum of 70 patients with ACAD9 deficiency: Is riboflavin supplementation effective?

Author

Repp, B, Mastantuono, E, Alston, C, Schiff, M, Haack, T, Rötig, A, Ardissone, A, Lombès, A, Catarino, C, Diodato, D, Schottmann, G, Poulton, J, Burlina, A, Jonckheere, A, Munnich, A, Rolinski, B, Ghezzi, D, Rokicki, D, Wellesley, D, Martinelli, D, Wenhong, D, Lamantea, E, Ostergaard, E, Pronicka, E, Pierre, G, Smeets, H, Wittig, I, Scurr, I, De Coo, I, Moroni, I, Smet, J, Mayr, J, Dai, L, De Meirleir, L, Schuelke, M, Zeviani, M, Morscher, R, Mcfarland, R, Seneca, S, Klopstock, T, Meitinger, T, Wieland, T, Strom, T, Herberg, U, Ahting, U, Sperl, W, Nassogne, M, Ling, H, Fang, F, Freisinger, P, Van Coster, R, Strecker, V, Taylor, R, Häberle, J, Vockley, J, Prokisch, H, Wortmann, S, Repp, Birgit M., Mastantuono, Elisa, Alston, Charlotte L., Schiff, Manuel, Haack, Tobias B., Rötig, Agnes, Ardissone, Anna, Lombès, Anne, Catarino, Claudia B., Diodato, Daria, Schottmann, Gudrun, Poulton, Joanna, Burlina, Alberto, Jonckheere, An, Munnich, Arnold, Rolinski, Boris, Ghezzi, Daniele, Rokicki, Dariusz, Wellesley, Diana, Martinelli, Diego, Wenhong, Ding, Lamantea, Eleonora, Ostergaard, Elsebet, Pronicka, Ewa, Pierre, Germaine, Smeets, Hubert J. M., Wittig, Ilka, Scurr, Ingrid, De Coo, Irenaeus F. M., Moroni, Isabella, Smet, Joél, Mayr, Johannes A., Dai, Lifang, De Meirleir, Linda, Schuelke, Markus, Zeviani, Massimo, Morscher, Raphael J., McFarland, Robert, Seneca, Sara, Klopstock, Thomas, Meitinger, Thomas, Wieland, Thomas, Strom, Tim M., Herberg, Ulrike, Ahting, Uwe, Sperl, Wolfgang, Nassogne, Marie-Cecile, Ling, Han, Fang, Fang, Freisinger, Peter, Van Coster, Rudy, Strecker, Valentina, Taylor, Robert W., Häberle, Johannes, Vockley, Jerry, Prokisch, Holger, Wortmann, Saskia, Repp, B, Mastantuono, E, Alston, C, Schiff, M, Haack, T, Rötig, A, Ardissone, A, Lombès, A, Catarino, C, Diodato, D, Schottmann, G, Poulton, J, Burlina, A, Jonckheere, A, Munnich, A, Rolinski, B, Ghezzi, D, Rokicki, D, Wellesley, D, Martinelli, D, Wenhong, D, Lamantea, E, Ostergaard, E, Pronicka, E, Pierre, G, Smeets, H, Wittig, I, Scurr, I, De Coo, I, Moroni, I, Smet, J, Mayr, J, Dai, L, De Meirleir, L, Schuelke, M, Zeviani, M, Morscher, R, Mcfarland, R, Seneca, S, Klopstock, T, Meitinger, T, Wieland, T, Strom, T, Herberg, U, Ahting, U, Sperl, W, Nassogne, M, Ling, H, Fang, F, Freisinger, P, Van Coster, R, Strecker, V, Taylor, R, Häberle, J, Vockley, J, Prokisch, H, Wortmann, S, Repp, Birgit M., Mastantuono, Elisa, Alston, Charlotte L., Schiff, Manuel, Haack, Tobias B., Rötig, Agnes, Ardissone, Anna, Lombès, Anne, Catarino, Claudia B., Diodato, Daria, Schottmann, Gudrun, Poulton, Joanna, Burlina, Alberto, Jonckheere, An, Munnich, Arnold, Rolinski, Boris, Ghezzi, Daniele, Rokicki, Dariusz, Wellesley, Diana, Martinelli, Diego, Wenhong, Ding, Lamantea, Eleonora, Ostergaard, Elsebet, Pronicka, Ewa, Pierre, Germaine, Smeets, Hubert J. M., Wittig, Ilka, Scurr, Ingrid, De Coo, Irenaeus F. M., Moroni, Isabella, Smet, Joél, Mayr, Johannes A., Dai, Lifang, De Meirleir, Linda, Schuelke, Markus, Zeviani, Massimo, Morscher, Raphael J., McFarland, Robert, Seneca, Sara, Klopstock, Thomas, Meitinger, Thomas, Wieland, Thomas, Strom, Tim M., Herberg, Ulrike, Ahting, Uwe, Sperl, Wolfgang, Nassogne, Marie-Cecile, Ling, Han, Fang, Fang, Freisinger, Peter, Van Coster, Rudy, Strecker, Valentina, Taylor, Robert W., Häberle, Johannes, Vockley, Jerry, Prokisch, Holger, and Wortmann, Saskia

Abstract

Background: Mitochondrial acyl-CoA dehydrogenase family member 9 (ACAD9) is essential for the assembly of mitochondrial respiratory chain complex I. Disease causing biallelic variants in ACAD9 have been reported in individuals presenting with lactic acidosis and cardiomyopathy. Results: We describe the genetic, clinical and biochemical findings in a cohort of 70 patients, of whom 29 previously unpublished. We found 34 known and 18 previously unreported variants in ACAD9. No patients harbored biallelic loss of function mutations, indicating that this combination is unlikely to be compatible with life. Causal pathogenic variants were distributed throughout the entire gene, and there was no obvious genotype-phenotype correlation. Most of the patients presented in the first year of life. For this subgroup the survival was poor (50% not surviving the first 2 years) comparing to patients with a later presentation (more than 90% surviving 10 years). The most common clinical findings were cardiomyopathy (85%), muscular weakness (75%) and exercise intolerance (72%). Interestingly, severe intellectual deficits were only reported in one patient and severe developmental delays in four patients. More than 70% of the patients were able to perform the same activities of daily living when compared to peers. Conclusions: Our data show that riboflavin treatment improves complex I activity in the majority of patient-derived fibroblasts tested. This effect was also reported for most of the treated patients and is mirrored in the survival data. In the patient group with disease-onset below 1 year of age, we observed a statistically-significant better survival for patients treated with riboflavin.

Published
2018

30. Clinical, biochemical and genetic spectrum of 70 patients with ACAD9 deficiency:is riboflavin supplementation effective?

Author

Repp, Birgit M, Mastantuono, Elisa, Alston, Charlotte L, Schiff, Manuel, Haack, Tobias B, Rötig, Agnes, Ardissone, Anna, Lombès, Anne, Catarino, Claudia B, Diodato, Daria, Schottmann, Gudrun, Poulton, Joanna, Burlina, Alberto, Jonckheere, An, Munnich, Arnold, Rolinski, Boris, Ghezzi, Daniele, Rokicki, Dariusz, Wellesley, Diana, Martinelli, Diego, Wenhong, Ding, Lamantea, Eleonora, Ostergaard, Elsebet, Pronicka, Ewa, Pierre, Germaine, Smeets, Hubert J M, Wittig, Ilka, Scurr, Ingrid, de Coo, Irenaeus F M, Moroni, Isabella, Smet, Joél, Mayr, Johannes A, Dai, Lifang, de Meirleir, Linda, Schuelke, Markus, Zeviani, Massimo, Morscher, Raphael J, McFarland, Robert, Seneca, Sara, Klopstock, Thomas, Meitinger, Thomas, Wieland, Thomas, Strom, Tim M, Herberg, Ulrike, Ahting, Uwe, Sperl, Wolfgang, Nassogne, Marie-Cecile, Ling, Han, Fang, Fang, Freisinger, Peter, Van Coster, Rudy, Strecker, Valentina, Taylor, Robert W, Häberle, Johannes, Vockley, Jerry, Prokisch, Holger, Wortmann, Saskia, Repp, Birgit M, Mastantuono, Elisa, Alston, Charlotte L, Schiff, Manuel, Haack, Tobias B, Rötig, Agnes, Ardissone, Anna, Lombès, Anne, Catarino, Claudia B, Diodato, Daria, Schottmann, Gudrun, Poulton, Joanna, Burlina, Alberto, Jonckheere, An, Munnich, Arnold, Rolinski, Boris, Ghezzi, Daniele, Rokicki, Dariusz, Wellesley, Diana, Martinelli, Diego, Wenhong, Ding, Lamantea, Eleonora, Ostergaard, Elsebet, Pronicka, Ewa, Pierre, Germaine, Smeets, Hubert J M, Wittig, Ilka, Scurr, Ingrid, de Coo, Irenaeus F M, Moroni, Isabella, Smet, Joél, Mayr, Johannes A, Dai, Lifang, de Meirleir, Linda, Schuelke, Markus, Zeviani, Massimo, Morscher, Raphael J, McFarland, Robert, Seneca, Sara, Klopstock, Thomas, Meitinger, Thomas, Wieland, Thomas, Strom, Tim M, Herberg, Ulrike, Ahting, Uwe, Sperl, Wolfgang, Nassogne, Marie-Cecile, Ling, Han, Fang, Fang, Freisinger, Peter, Van Coster, Rudy, Strecker, Valentina, Taylor, Robert W, Häberle, Johannes, Vockley, Jerry, Prokisch, Holger, and Wortmann, Saskia

Abstract

BACKGROUND: Mitochondrial acyl-CoA dehydrogenase family member 9 (ACAD9) is essential for the assembly of mitochondrial respiratory chain complex I. Disease causing biallelic variants in ACAD9 have been reported in individuals presenting with lactic acidosis and cardiomyopathy.RESULTS: We describe the genetic, clinical and biochemical findings in a cohort of 70 patients, of whom 29 previously unpublished. We found 34 known and 18 previously unreported variants in ACAD9. No patients harbored biallelic loss of function mutations, indicating that this combination is unlikely to be compatible with life. Causal pathogenic variants were distributed throughout the entire gene, and there was no obvious genotype-phenotype correlation. Most of the patients presented in the first year of life. For this subgroup the survival was poor (50% not surviving the first 2 years) comparing to patients with a later presentation (more than 90% surviving 10 years). The most common clinical findings were cardiomyopathy (85%), muscular weakness (75%) and exercise intolerance (72%). Interestingly, severe intellectual deficits were only reported in one patient and severe developmental delays in four patients. More than 70% of the patients were able to perform the same activities of daily living when compared to peers.CONCLUSIONS: Our data show that riboflavin treatment improves complex I activity in the majority of patient-derived fibroblasts tested. This effect was also reported for most of the treated patients and is mirrored in the survival data. In the patient group with disease-onset below 1 year of age, we observed a statistically-significant better survival for patients treated with riboflavin.

Published
2018

31. Clinical, biochemical and genetic spectrum of 70 patients with ACAD9 deficiency: is riboflavin supplementation effective?

Author

Repp, Birgit M., Mastantuono, Elisa, Alston, Charlotte L., Schiff, Manuel, Haack, Tobias B., Rotig, Agnes, Ardissone, Anna, Lombes, Anne, Catarino, Claudia B., Diodato, Daria, Schottmann, Gudrun, Poulton, Joanna, Burlina, Alberto, Jonckheere, An, Munnich, Arnold, Rolinski, Boris, Ghezzi, Daniele, Rokicki, Dariusz, Wellesley, Diana, Martinelli, Diego, Ding, Wenhong, Lamantea, Eleonora, Ostergaard, Elsebet, Pronicka, Ewa, Pierre, Germaine, Smeets, Hubert J. M., Wittig, Ilka, Scurr, Ingrid, de Coo, Irenaeus F. M., Moroni, Isabella, Smet, Joel, Mayr, Johannes A., Dai, Lifang, de Meirleir, Linda, Schuelke, Markus, Zeviani, Massimo, Morscher, Raphael J., McFarland, Robert, Seneca, Sara, Klopstock, Thomas, Meitinger, Thomas, Wieland, Thomas, Strom, Tim M., Herberg, Ulrike, Ahting, Uwe, Sperl, Wolfgang, Nassogne, Marie-Cecile, Ling, Han, Fang, Fang, Freisinger, Peter, Van Coster, Rudy, Strecker, Valentina, Taylor, Robert W., Haberle, Johannes, Vockley, Jerry, Prokisch, Holger, Wortmann, Saskia, UCL - SSS/IONS - Institute of NeuroScience, UCL - SSS/IONS/NEUR - Clinical Neuroscience, UCL - (SLuc) Service de neurologie pédiatrique, Repp, B, Mastantuono, E, Alston, C, Schiff, M, Haack, T, Rötig, A, Ardissone, A, Lombès, A, Catarino, C, Diodato, D, Schottmann, G, Poulton, J, Burlina, A, Jonckheere, A, Munnich, A, Rolinski, B, Ghezzi, D, Rokicki, D, Wellesley, D, Martinelli, D, Wenhong, D, Lamantea, E, Ostergaard, E, Pronicka, E, Pierre, G, Smeets, H, Wittig, I, Scurr, I, De Coo, I, Moroni, I, Smet, J, Mayr, J, Dai, L, De Meirleir, L, Schuelke, M, Zeviani, M, Morscher, R, Mcfarland, R, Seneca, S, Klopstock, T, Meitinger, T, Wieland, T, Strom, T, Herberg, U, Ahting, U, Sperl, W, Nassogne, M, Ling, H, Fang, F, Freisinger, P, Van Coster, R, Strecker, V, Taylor, R, Häberle, J, Vockley, J, Prokisch, H, Wortmann, S, Apollo - University of Cambridge Repository, Reproduction and Genetics, Neurogenetics, Clinical sciences, Pediatrics, Medical Genetics, Neurology, RS: GROW - R4 - Reproductive and Perinatal Medicine, Klinische Genetica, and RS: FHML MaCSBio

Subjects
Electron Transport Complex I/metabolism, Male, Mitochondrial Diseases, genetics [Mitochondrial Diseases], PHENOTYPIC SPECTRUM, Riboflavin, therapeutic use [Riboflavin], lcsh:Medicine, Acidosis/genetics, Heart transplantation, OXIDATION, Acyl-CoA Dehydrogenase, drug therapy [Muscle Weakness], Neonatal, Activities Of Daily Living, Cardiomyopathy, Complex I, Heart Transplantation, Lactic Acidosis, Mitochondrial Disorder, Prognosis, Treatment, Vitamin, Activities of Daily Living, Medicine and Health Sciences, Genetics(clinical), Pharmacology (medical), Amino Acid Metabolism, Inborn Errors/genetics, Genetics (clinical), Cardiomyopathy, Hypertrophic/genetics, Muscle Weakness, genetics [Cardiomyopathy, Hypertrophic], Lactic acidosis, Inborn Errors, Activities of daily living, Riboflavin/therapeutic use, Mitochondrial disorder, metabolism [Acidosis], Lactic acidosi, metabolism [Mitochondrial Diseases], Acidosis, Amino Acid Metabolism, Inborn Errors, Cardiomyopathy, Hypertrophic, Electron Transport Complex I, Female, Humans, genetics [Muscle Weakness], SKELETAL-MUSCLE, pathology [Cardiomyopathy, Hypertrophic], pathology [Amino Acid Metabolism, Inborn Errors], DISORDERS, Prognosi, metabolism [Cardiomyopathy, Hypertrophic], pathology [Acidosis], Mitochondrial Diseases/genetics, DIAGNOSIS, metabolism [Acyl-CoA Dehydrogenase], Muscle Weakness/drug therapy, genetics [Amino Acid Metabolism, Inborn Errors], ddc:610, metabolism [Electron Transport Complex I], pathology [Muscle Weakness], MUTATIONS, deficiency [Acyl-CoA Dehydrogenase], Research, lcsh:R, Biology and Life Sciences, metabolism [Muscle Weakness], BEZAFIBRATE, Acyl-CoA Dehydrogenase/deficiency, metabolism [Amino Acid Metabolism, Inborn Errors], PAGE, Amino Acid Metabolism, pathology [Mitochondrial Diseases], Hypertrophic, CELLS, COMPLEX-I DEFICIENCY, genetics [Acidosis], Human medicine, genetics [Acyl-CoA Dehydrogenase]
Abstract

Background Mitochondrial acyl-CoA dehydrogenase family member 9 (ACAD9) is essential for the assembly of mitochondrial respiratory chain complex I. Disease causing biallelic variants in ACAD9 have been reported in individuals presenting with lactic acidosis and cardiomyopathy. Results We describe the genetic, clinical and biochemical findings in a cohort of 70 patients, of whom 29 previously unpublished. We found 34 known and 18 previously unreported variants in ACAD9. No patients harbored biallelic loss of function mutations, indicating that this combination is unlikely to be compatible with life. Causal pathogenic variants were distributed throughout the entire gene, and there was no obvious genotype-phenotype correlation. Most of the patients presented in the first year of life. For this subgroup the survival was poor (50% not surviving the first 2 years) comparing to patients with a later presentation (more than 90% surviving 10 years). The most common clinical findings were cardiomyopathy (85%), muscular weakness (75%) and exercise intolerance (72%). Interestingly, severe intellectual deficits were only reported in one patient and severe developmental delays in four patients. More than 70% of the patients were able to perform the same activities of daily living when compared to peers. Conclusions Our data show that riboflavin treatment improves complex I activity in the majority of patient-derived fibroblasts tested. This effect was also reported for most of the treated patients and is mirrored in the survival data. In the patient group with disease-onset below 1 year of age, we observed a statistically-significant better survival for patients treated with riboflavin. Electronic supplementary material The online version of this article (10.1186/s13023-018-0784-8) contains supplementary material, which is available to authorized users.

Published
2017

32. Biallelic C1QBP Mutations Cause Severe Neonatal-, Childhood-, or Later-Onset Cardiomyopathy Associated with Combined Respiratory-Chain Deficiencies

Author

Feichtinger, René G., Oláhová, Monika, Kishita, Yoshihito, Garone, Caterina, Kremer, Laura S., Yagi, Mikako, Uchiumi, Takeshi, Jourdain, Alexis A., Thompson, Kyle, D’Souza, Aaron R., Kopajtich, Robert, Alston, Charlotte L., Koch, Johannes, Sperl, Wolfgang, Mastantuono, Elisa, Strom, Tim M., Wortmann, Saskia B., Meitinger, Thomas, Pierre, Germaine, Chinnery, Patrick F., Chrzanowska-Lightowlers, Zofia M., Lightowlers, Robert N., DiMauro, Salvatore, Calvo, Sarah E., Mootha, Vamsi K., Moggio, Maurizio, Sciacco, Monica, Comi, Giacomo P., Ronchi, Dario, Murayama, Kei, Ohtake, Akira, Rebelo-Guiomar, Pedro, Kohda, Masakazu, Kang, Dongchon, Mayr, Johannes A., Taylor, Robert W., Okazaki, Yasushi, Minczuk, Michal, and Prokisch, Holger

Subjects
ddc
Published
2017

33. Early‐onset coenzyme Q10 deficiency associated with ataxia and respiratory chain dysfunction due to novel pathogenic COQ8A variants, including a large intragenic deletion.

Author

Cotta, Ana, Alston, Charlotte L., Baptista‐Junior, Sidney, Paim, Julia F., Carvalho, Elmano, Navarro, Monica M., Appleton, Marie, Ng, Yi Shiau, Valicek, Jaquelin, da‐Cunha‐Junior, Antonio L., Lima, Maria I., Rocque Ferreira, Alessandra, Takata, Reinaldo I., Hargreaves, Iain P., Gorman, Gráinne S., McFarland, Robert, Pierre, Germaine, and Taylor, Robert W.

Published
2020
Full Text
View/download PDF

35. P19 Clinical pearl: pharmaceutical management of siblings with guanidinoacetate methyltransferase (gamt) deficiency

Author

Guilder Laura, Hogg Sarah, Batten William, and Pierre Germaine

Subjects
medicine.medical_specialty, Arginine, business.industry, Nonsense mutation, Neurotoxicity, Ornithine, Creatine, medicine.disease, Guanidinoacetate N-methyltransferase, chemistry.chemical_compound, Endocrinology, chemistry, Internal medicine, Pediatrics, Perinatology and Child Health, Speech delay, medicine, medicine.symptom, business, Energy source
Abstract

SituationPatient A and B are 9 and 4 year old siblings with developmental delay and in particular; speech delay, seizures and behavioural difficulties. They were found to have GAMT deficiency due to a heterozygous pathogenic GAMT splicing mutation c.327G>A and pathogenic GAMT nonsense mutation c.522G>A (Trp174Ter). Patient A and B were referred to the regional metabolic team for further input. Management of this rare disorder involves combination treatment with specialist medications and a protein restricted diet.1,2BackgroundGAMT deficiency is an inherited disorder of creatine synthesis.1,2 Approximately 110 patients have been diagnosed world wide.1 Main clinical features are intellectual disability with speech and language delay, behavioural problems and epilepsy.1,2 Creatine is an important energy source formuscle and brain. The enzyme arginine: amidinotransferase (AGAT) synthesises guanidinoacetate (GAA) using arginine and glycineas substrates.1,2 The enzyme GAMT in the liver then catalyses the last step of creatine synthesis converting GAA into creatine.1,2 Creatine is transported via the bloodstream to other organs where it is utilised.1 In GAMT deficiency there is a deficiency of creatine and an excess of GAA causing neurotoxicity. The sibling’s history and presentation were consistent with GAMT deficiency and plasma GAA levels done before starting ornithine were very elevated confirming the genetic finding.TreatmentCreatine supplementation restores deficient levels. L-Ornithine competitively inhibits the enzyme AGAT reducing GAA synthesis. An arginine restricted diet and sodium benzoate deprives the pathway of arginine and glycine respectively reducing GAA synthesis.1,2Outcome6 months after starting treatment with creatine (400 mg/kg/day) and l-ornithine (400 mg/kg/day), a significant clinical improvement has been observed. Patient A has had improvement in memory recall, speech and sleeping, and her seizures have reduced from daily to occasionally. Her plasma GAA levels have decreased from 13.3 to 6.5 micromoles/L (0.8–3.1 micromole/L).A bigger improvement has been seen for patient B, probably explained by an earlier age of intervention. Seizures have stopped, with normalisation of his electroencephalogram. His behaviour, attention span and speech have improved, with an ability to form sentences and a widening vocabulary. He is able to walk up the stairs rather than crawl or bottom-shuffle. His plasma GAA has decreased from 14.7 to 8.0 micromoles/L.Doses of l-ornithine and creatine have been increased further to 600 mg/kg/day.Both have had brain magnetic resonance spectroscopy on treatment showing there is no creatine deficiency.Lessons learntManagement of GAMT deficiency requires multidisciplinary input with pharmacy playing an important role advising on treatment, dosing and formulation, and sourcing ornithine and creatine of pharmaceutical grade that is palatable for children. As with very rare disorders, recommendations for treatment are based on case reports and expert opinion. However, there is an emerging pattern that combined treatment started early has the best outcome with normal development sometimes being reported. The siblings struggled with the diet so pharmaceutical intervention is the mainstay of management. If GAA levels fail to fall and/or remain low then sodium benzoate may be introduced.1ReferencesSaudubray JM, Baumgartner MR, Walter J. Inborn metabolic diseases: Diagnosis and treatment 2016;6th ed. Berlin: Springer.Stockler-Ipsiroglu S, Van Karnebeek C, Longo N, et al. Guanidinoacetate methyltransferase (GAMT) deficiency: Outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring. Molecular Genetics and Metabolism2014;111:16–25.

Published
2018

36. Biallelic C1QBP Mutations Cause Severe Neonatal-, Childhood-, or Later-Onset Cardiomyopathy Associated with Combined Respiratory-Chain Deficiencies

Author

Feichtinger, René G., primary, Oláhová, Monika, additional, Kishita, Yoshihito, additional, Garone, Caterina, additional, Kremer, Laura S., additional, Yagi, Mikako, additional, Uchiumi, Takeshi, additional, Jourdain, Alexis A., additional, Thompson, Kyle, additional, D’Souza, Aaron R., additional, Kopajtich, Robert, additional, Alston, Charlotte L., additional, Koch, Johannes, additional, Sperl, Wolfgang, additional, Mastantuono, Elisa, additional, Strom, Tim M., additional, Wortmann, Saskia B., additional, Meitinger, Thomas, additional, Pierre, Germaine, additional, Chinnery, Patrick F., additional, Chrzanowska-Lightowlers, Zofia M., additional, Lightowlers, Robert N., additional, DiMauro, Salvatore, additional, Calvo, Sarah E., additional, Mootha, Vamsi K., additional, Moggio, Maurizio, additional, Sciacco, Monica, additional, Comi, Giacomo P., additional, Ronchi, Dario, additional, Murayama, Kei, additional, Ohtake, Akira, additional, Rebelo-Guiomar, Pedro, additional, Kohda, Masakazu, additional, Kang, Dongchon, additional, Mayr, Johannes A., additional, Taylor, Robert W., additional, Okazaki, Yasushi, additional, Minczuk, Michal, additional, and Prokisch, Holger, additional

Published
2017
Full Text
View/download PDF

40. An Unusual Cause of Progressive Ataxia and Devastating Seizure Disorder (S20.003)

Author

Ng, Yi Shiau, primary, Alston, Charlotte, additional, Blakely, Emma, additional, Lax, Nichola, additional, Pierre, Germaine, additional, Chronopoulou, Efstathia, additional, Riordan, Gill, additional, Mundy, Helen, additional, Champion, Michael, additional, Maddison, Paul, additional, Chinnery, Patrick, additional, Taylor, Robert, additional, Turnbull, Doug, additional, McFarland, Robert, additional, and Gorman, Grainne, additional

Published
2016
Full Text
View/download PDF

42. I-cell disease: The experience of six centres

Author

Jameson, Elisabeth, primary, Wilson, Barbara, additional, Santra, Saikat, additional, Broomfield, Alexander, additional, McElligott, Fiona, additional, Crushell, Ellen, additional, Stewart, Fiona, additional, Pierre, Germaine, additional, Powers, Victoria, additional, Wraith, Ed, additional, and Jones, Simon, additional

Published
2013
Full Text
View/download PDF

43. Additional file 3: of Clinical, biochemical and genetic spectrum of 70 patients with ACAD9 deficiency: is riboflavin supplementation effective?

Author

Repp, Birgit, Mastantuono, Elisa, Alston, Charlotte, Schiff, Manuel, Haack, Tobias, RÜtig, Agnes, Ardissone, Anna, LombèS, Anne, Catarino, Claudia, Diodato, Daria, Schottmann, Gudrun, Poulton, Joanna, Burlina, Alberto, Jonckheere, An, Munnich, Arnold, Rolinski, Boris, Ghezzi, Daniele, Rokicki, Dariusz, Wellesley, Diana, Martinelli, Diego, Wenhong, Ding, Lamantea, Eleonora, Ostergaard, Elsebet, Pronicka, Ewa, Pierre, Germaine, Smeets, Hubert, Wittig, Ilka, Scurr, Ingrid, Irenaeus De Coo, Moroni, Isabella, JoÊl Smet, Mayr, Johannes, Lifang Dai, Meirleir, Linda De, Schuelke, Markus, Zeviani, Massimo, Morscher, Raphael, McFarland, Robert, Seneca, Sara, Klopstock, Thomas, Meitinger, Thomas, Wieland, Thomas, Strom, Tim, Herberg, Ulrike, Ahting, Uwe, Sperl, Wolfgang, Marie-Cecile Nassogne, Ling, Han, Fang, Fang, Freisinger, Peter, Coster, Rudy Van, Strecker, Valentina, Taylor, Robert, HäBerle, Johannes, Vockley, Jerry, Prokisch, Holger, and Wortmann, Saskia

Subjects
3. Good health
Abstract

Table S2. Calculation of European incidence of ACAD9 deficiency (DOCX 36Â kb)

44. Clinical presentation and proteomic signature of patients with TANGO2 mutations

Author

Mingirulli, Nadja, Pyle, Angela, Hathazi, Denisa, Alston, Charlotte L, Kohlschmidt, Nicolai, O'Grady, Gina, Waddell, Leigh, Evesson, Frances, Cooper, Sandra BT, Turner, Christian, Duff, Jennifer, Topf, Ana, Yubero, Delia, Jou, Cristina, Nascimento, Andrés, Ortez, Carlos, García-Cazorla, Angels, Gross, Claudia, O'Callaghan, Maria, Santra, Saikat, Preece, Maryanne A, Champion, Michael, Korenev, Sergei, Chronopoulou, Efsthatia, Anirban, Majumdar, Pierre, Germaine, McArthur, Daniel, Thompson, Kyle, Navas, Placido, Ribes, Antonia, Tort, Frederic, Schlüter, Agatha, Pujol, Aurora, Montero, Raquel, Sarquella, Georgia, Lochmüller, Hanns, Jiménez-Mallebrera, Cecilia, Taylor, Robert W, Artuch, Rafael, Kirschner, Janbernd, Grünert, Sarah C, Roos, Andreas, and Horvath, Rita

Subjects
Male, Proteomics, Mitochondrial Diseases, Muscle Weakness, Whole Genome Sequencing, Brain Diseases, Metabolic, Fatty Acids, Homozygote, Golgi Apparatus, Infant, proteomic analysis, Oxidative Phosphorylation, Rhabdomyolysis, 3. Good health, Phenotype, fatty acid metabolism, TANGO2, metabolic encephalomyopathy, mitochondrial dysfunction, Mutation, Humans, Female
Abstract

Transport And Golgi Organization protein 2 (TANGO2) deficiency has recently been identified as a rare metabolic disorder with a distinct clinical and biochemical phenotype of recurrent metabolic crises, hypoglycemia, lactic acidosis, rhabdomyolysis, arrhythmias, and encephalopathy with cognitive decline. We report nine subjects from seven independent families, and we studied muscle histology, respiratory chain enzyme activities in skeletal muscle and proteomic signature of fibroblasts. All nine subjects carried autosomal recessive TANGO2 mutations. Two carried the reported deletion of exons 3 to 9, one homozygous, one heterozygous with a 22q11.21 microdeletion inherited in trans. The other subjects carried three novel homozygous (c.262C>T/p.Arg88*; c.220A>C/p.Thr74Pro; c.380+1G>A), and two further novel heterozygous (c.6_9del/p.Phe6del); c.11-13delTCT/p.Phe5del mutations. Immunoblot analysis detected a significant decrease of TANGO2 protein. Muscle histology showed mild variation of fiber diameter, no ragged-red/cytochrome c oxidase-negative fibers and a defect of multiple respiratory chain enzymes and coenzyme Q10 (CoQ10 ) in two cases, suggesting a possible secondary defect of oxidative phosphorylation. Proteomic analysis in fibroblasts revealed significant changes in components of the mitochondrial fatty acid oxidation, plasma membrane, endoplasmic reticulum-Golgi network and secretory pathways. Clinical presentation of TANGO2 mutations is homogeneous and clinically recognizable. The hemizygous mutations in two patients suggest that some mutations leading to allele loss are difficult to detect. A combined defect of the respiratory chain enzymes and CoQ10 with altered levels of several membrane proteins provides molecular insights into the underlying pathophysiology and may guide rational new therapeutic interventions.

45. Additional file 2: of Clinical, biochemical and genetic spectrum of 70 patients with ACAD9 deficiency: is riboflavin supplementation effective?

Author

Repp, Birgit, Mastantuono, Elisa, Alston, Charlotte, Schiff, Manuel, Haack, Tobias, RÜtig, Agnes, Ardissone, Anna, LombèS, Anne, Catarino, Claudia, Diodato, Daria, Schottmann, Gudrun, Poulton, Joanna, Burlina, Alberto, Jonckheere, An, Munnich, Arnold, Rolinski, Boris, Ghezzi, Daniele, Rokicki, Dariusz, Wellesley, Diana, Martinelli, Diego, Wenhong, Ding, Lamantea, Eleonora, Ostergaard, Elsebet, Pronicka, Ewa, Pierre, Germaine, Smeets, Hubert, Wittig, Ilka, Scurr, Ingrid, Irenaeus De Coo, Moroni, Isabella, JoÊl Smet, Mayr, Johannes, Lifang Dai, Meirleir, Linda De, Schuelke, Markus, Zeviani, Massimo, Morscher, Raphael, McFarland, Robert, Seneca, Sara, Klopstock, Thomas, Meitinger, Thomas, Wieland, Thomas, Strom, Tim, Herberg, Ulrike, Ahting, Uwe, Sperl, Wolfgang, Marie-Cecile Nassogne, Ling, Han, Fang, Fang, Freisinger, Peter, Coster, Rudy Van, Strecker, Valentina, Taylor, Robert, HäBerle, Johannes, Vockley, Jerry, Prokisch, Holger, and Wortmann, Saskia

Subjects
3. Good health
Abstract

Table S1. Compound heterozygous and homozygous ACAD9 variants identified in 67 patients present in this study (DOCX 75Â kb)

46. Additional file 1: of Clinical, biochemical and genetic spectrum of 70 patients with ACAD9 deficiency: is riboflavin supplementation effective?

Author

Repp, Birgit, Mastantuono, Elisa, Alston, Charlotte, Schiff, Manuel, Haack, Tobias, RÜtig, Agnes, Ardissone, Anna, LombèS, Anne, Catarino, Claudia, Diodato, Daria, Schottmann, Gudrun, Poulton, Joanna, Burlina, Alberto, Jonckheere, An, Munnich, Arnold, Rolinski, Boris, Ghezzi, Daniele, Rokicki, Dariusz, Wellesley, Diana, Martinelli, Diego, Wenhong, Ding, Lamantea, Eleonora, Ostergaard, Elsebet, Pronicka, Ewa, Pierre, Germaine, Smeets, Hubert, Wittig, Ilka, Scurr, Ingrid, Irenaeus De Coo, Moroni, Isabella, JoÊl Smet, Mayr, Johannes, Lifang Dai, Meirleir, Linda De, Schuelke, Markus, Zeviani, Massimo, Morscher, Raphael, McFarland, Robert, Seneca, Sara, Klopstock, Thomas, Meitinger, Thomas, Wieland, Thomas, Strom, Tim, Herberg, Ulrike, Ahting, Uwe, Sperl, Wolfgang, Marie-Cecile Nassogne, Ling, Han, Fang, Fang, Freisinger, Peter, Coster, Rudy Van, Strecker, Valentina, Taylor, Robert, HäBerle, Johannes, Vockley, Jerry, Prokisch, Holger, and Wortmann, Saskia

Subjects
3. Good health
Abstract

Additional data. (DOCX 38Â kb)

47. Additional file 5: of Clinical, biochemical and genetic spectrum of 70 patients with ACAD9 deficiency: is riboflavin supplementation effective?

Author

Repp, Birgit, Mastantuono, Elisa, Alston, Charlotte, Schiff, Manuel, Haack, Tobias, Rötig, Agnes, Ardissone, Anna, Lombès, Anne, Catarino, Claudia, Diodato, Daria, Schottmann, Gudrun, Poulton, Joanna, Burlina, Alberto, Jonckheere, An, Munnich, Arnold, Rolinski, Boris, Ghezzi, Daniele, Rokicki, Dariusz, Wellesley, Diana, Martinelli, Diego, Wenhong, Ding, Lamantea, Eleonora, Ostergaard, Elsebet, Pronicka, Ewa, Pierre, Germaine, Smeets, Hubert, Wittig, Ilka, Scurr, Ingrid, Irenaeus De Coo, Moroni, Isabella, Joél Smet, Mayr, Johannes, Lifang Dai, Meirleir, Linda De, Schuelke, Markus, Zeviani, Massimo, Morscher, Raphael, McFarland, Robert, Seneca, Sara, Klopstock, Thomas, Meitinger, Thomas, Wieland, Thomas, Strom, Tim, Herberg, Ulrike, Ahting, Uwe, Sperl, Wolfgang, Marie-Cecile Nassogne, Ling, Han, Fang, Fang, Freisinger, Peter, Coster, Rudy Van, Strecker, Valentina, Taylor, Robert, Häberle, Johannes, Vockley, Jerry, Prokisch, Holger, and Wortmann, Saskia

Subjects
3. Good health
Abstract

Figure S1. Representative picture of Complex I assembly in fibroblasts of individual 1 (A, upper panels) Two-dimensional BN/SDS-PAGE separation and quantification of fluorescent-labelled mitochondrial complexes from 10 mg patient (left) and control fibroblasts (right) are shown. (A, lower panels) show silver stained 2 D gels. (B) Quantified Supercomplexes in 2D gels from control and patient fibroblast with and without bezafibrate treatment for 72 h. (C) Panoramaplots of 2D gels with assignment of signals used for quantification of complexes. Assignment of complexes: O, OGDC, oxoglutarate dehydrogenase complex; V, complex V or ATP synthase; III, complex III or cytochrome c reductase; IV, complex IV or cytochrome c oxidase; S, supercomplexes composed of respiratory chain complexes I, III, and IV. 2-D gels were scanned side by side for direct comparison and are shown as pseudocolors. (pdf). (PDF 1109 kb)

48. Additional file 4: of Clinical, biochemical and genetic spectrum of 70 patients with ACAD9 deficiency: is riboflavin supplementation effective?

Author

Repp, Birgit, Mastantuono, Elisa, Alston, Charlotte, Schiff, Manuel, Haack, Tobias, RÜtig, Agnes, Ardissone, Anna, LombèS, Anne, Catarino, Claudia, Diodato, Daria, Schottmann, Gudrun, Poulton, Joanna, Burlina, Alberto, Jonckheere, An, Munnich, Arnold, Rolinski, Boris, Ghezzi, Daniele, Rokicki, Dariusz, Wellesley, Diana, Martinelli, Diego, Wenhong, Ding, Lamantea, Eleonora, Ostergaard, Elsebet, Pronicka, Ewa, Pierre, Germaine, Smeets, Hubert, Wittig, Ilka, Scurr, Ingrid, Irenaeus De Coo, Moroni, Isabella, JoÊl Smet, Mayr, Johannes, Lifang Dai, Meirleir, Linda De, Schuelke, Markus, Zeviani, Massimo, Morscher, Raphael, McFarland, Robert, Seneca, Sara, Klopstock, Thomas, Meitinger, Thomas, Wieland, Thomas, Strom, Tim, Herberg, Ulrike, Ahting, Uwe, Sperl, Wolfgang, Marie-Cecile Nassogne, Ling, Han, Fang, Fang, Freisinger, Peter, Coster, Rudy Van, Strecker, Valentina, Taylor, Robert, HäBerle, Johannes, Vockley, Jerry, Prokisch, Holger, and Wortmann, Saskia

Subjects
3. Good health
Abstract

Table S3. Clinical characteristics of the 67 patients present in this study (DOCX 72Â kb)

49. Additional file 5: of Clinical, biochemical and genetic spectrum of 70 patients with ACAD9 deficiency: is riboflavin supplementation effective?

Author

Repp, Birgit, Mastantuono, Elisa, Alston, Charlotte, Schiff, Manuel, Haack, Tobias, Rötig, Agnes, Ardissone, Anna, Lombès, Anne, Catarino, Claudia, Diodato, Daria, Schottmann, Gudrun, Poulton, Joanna, Burlina, Alberto, Jonckheere, An, Munnich, Arnold, Rolinski, Boris, Ghezzi, Daniele, Rokicki, Dariusz, Wellesley, Diana, Martinelli, Diego, Wenhong, Ding, Lamantea, Eleonora, Ostergaard, Elsebet, Pronicka, Ewa, Pierre, Germaine, Smeets, Hubert, Wittig, Ilka, Scurr, Ingrid, Irenaeus De Coo, Moroni, Isabella, Joél Smet, Mayr, Johannes, Lifang Dai, Meirleir, Linda De, Schuelke, Markus, Zeviani, Massimo, Morscher, Raphael, McFarland, Robert, Seneca, Sara, Klopstock, Thomas, Meitinger, Thomas, Wieland, Thomas, Strom, Tim, Herberg, Ulrike, Ahting, Uwe, Sperl, Wolfgang, Marie-Cecile Nassogne, Ling, Han, Fang, Fang, Freisinger, Peter, Coster, Rudy Van, Strecker, Valentina, Taylor, Robert, Häberle, Johannes, Vockley, Jerry, Prokisch, Holger, and Wortmann, Saskia

Subjects
3. Good health
Abstract

Figure S1. Representative picture of Complex I assembly in fibroblasts of individual 1 (A, upper panels) Two-dimensional BN/SDS-PAGE separation and quantification of fluorescent-labelled mitochondrial complexes from 10 mg patient (left) and control fibroblasts (right) are shown. (A, lower panels) show silver stained 2 D gels. (B) Quantified Supercomplexes in 2D gels from control and patient fibroblast with and without bezafibrate treatment for 72 h. (C) Panoramaplots of 2D gels with assignment of signals used for quantification of complexes. Assignment of complexes: O, OGDC, oxoglutarate dehydrogenase complex; V, complex V or ATP synthase; III, complex III or cytochrome c reductase; IV, complex IV or cytochrome c oxidase; S, supercomplexes composed of respiratory chain complexes I, III, and IV. 2-D gels were scanned side by side for direct comparison and are shown as pseudocolors. (pdf). (PDF 1109 kb)

50. Additional file 3: of Clinical, biochemical and genetic spectrum of 70 patients with ACAD9 deficiency: is riboflavin supplementation effective?

Author

Repp, Birgit, Mastantuono, Elisa, Alston, Charlotte, Schiff, Manuel, Haack, Tobias, RÜtig, Agnes, Ardissone, Anna, LombèS, Anne, Catarino, Claudia, Diodato, Daria, Schottmann, Gudrun, Poulton, Joanna, Burlina, Alberto, Jonckheere, An, Munnich, Arnold, Rolinski, Boris, Ghezzi, Daniele, Rokicki, Dariusz, Wellesley, Diana, Martinelli, Diego, Wenhong, Ding, Lamantea, Eleonora, Ostergaard, Elsebet, Pronicka, Ewa, Pierre, Germaine, Smeets, Hubert, Wittig, Ilka, Scurr, Ingrid, Irenaeus De Coo, Moroni, Isabella, JoÊl Smet, Mayr, Johannes, Lifang Dai, Meirleir, Linda De, Schuelke, Markus, Zeviani, Massimo, Morscher, Raphael, McFarland, Robert, Seneca, Sara, Klopstock, Thomas, Meitinger, Thomas, Wieland, Thomas, Strom, Tim, Herberg, Ulrike, Ahting, Uwe, Sperl, Wolfgang, Marie-Cecile Nassogne, Ling, Han, Fang, Fang, Freisinger, Peter, Coster, Rudy Van, Strecker, Valentina, Taylor, Robert, HäBerle, Johannes, Vockley, Jerry, Prokisch, Holger, and Wortmann, Saskia

Subjects
3. Good health
Abstract

Table S2. Calculation of European incidence of ACAD9 deficiency (DOCX 36Â kb)

Catalog

Books, media, physical & digital resources
See catalog results